Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
StageZero Life Sciences Ltd
61N1Current price
0.018 EUR
+0.000000000046 EUR (+0.00%)
Last closed
0.04 CAD
Company
www.stagezerolifesciences.com
ISIN
CA8525403017
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
Frankfurt Exchange
Capitalization
4 946 000 CAD
Yield for 12 month
-27.27 %
1Y
3Y
5Y
10Y
15Y
61N1
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada. Address: 70 East Beaver Creek Road, Richmond Hill, ON, Canada, L4B 3B2
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1.74 CADP/E ratio
–Dividend Yield
–Current Year
+4 009 040 CAD
Last Year
+5 278 727 CAD
Current Quarter
+542 582 CAD
Last Quarter
+725 961 CAD
Current Year
+14 398 CAD
Last Year
-561 588 CAD
Current Quarter
+10 874 CAD
Last Quarter
+418 038 CAD
Key Figures 61N1
1 year
3 years
5 years
10 years
EBITDA
-4 467 501 CAD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-63.8 %
PEG Ratio
–
Return On Equity TTM
-168.85 %
Wall Street Target Price
1.74 CAD
Revenue TTM
2 996 141 CAD
Book Value
-0.083 CAD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-33 %
Dividend Yield
–
Gross Profit TTM
1 178 408 CAD
Earnings per share
-0.16 CAD
Diluted Eps TTM
-0.16 CAD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
1319.8 %
Profit Margin
–
Dividend Analytics 61N1
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 61N1
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:8
Payout Ratio
–
Last Split Date
18.09.2020
Dividend Date
18.09.2020
Stock Valuation 61N1
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
3.367
Enterprise Value Revenue
2.3369
Price Sales TTM
1.7031
Enterprise Value EBITDA
-0.5648
Price Book MRQ
5.9366
Financials 61N1
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 61N1
For 52 weeks
0.04 CAD
0.06 CAD
50 Day MA
0.04 CAD
Shares Short Prior Month
39 707
200 Day MA
0.046 CAD
Short Ratio
0.5
Shares Short
39 707
Short Percent
0.23 %
BeatStart